Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973721 | 0.93 | SIRT2 (0.60) | SIRT2NR1H4ALDH1A1TP53TYR | |
| SCHEMBL3977772 | 0.92 | SIRT2 (0.56) | SIRT2NR1H4ALDH1A1TP53TYR | |
| SCHEMBL3979665 | 0.91 | SIRT2 (0.55) | SIRT2NR1H4ALDH1A1TP53TYR | |
| SCHEMBL3975811 | 0.91 | SIRT2 (0.55) | SIRT2NR1H4ALDH1A1TP53TYR | |
| SCHEMBL3980739 | 0.91 | SIRT2 (0.55) | SIRT2NR1H4ALDH1A1TP53TYR | |
| SCHEMBL3982862 | 0.91 | SIRT2 (0.55) | SIRT2NR1H4ALDH1A1TP53TYR | |
| SCHEMBL3973757 | 0.87 | ALDH1A1 (0.53) | SIRT2NR1H4ALDH1A1TP53TYR | |
| SCHEMBL3977087 | 0.87 | PRSS1 (0.54) | SIRT2ALDH1A1TP53TYRTSHR | |
| SCHEMBL3977061 | 0.86 | ALDH1A1 (0.51) | SIRT2ALDH1A1TP53TYRTSHR | |
| SCHEMBL3978614 | 0.86 | ALDH1A1 (0.51) | SIRT2ALDH1A1TP53TYRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | claimed |
| CN-1849301-A | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS INC (US) | 2006-10-18 | — | — | CN | claimed |
| EP-1648862-A2 | SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2006-04-26 | — | — | EP | claimed |
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | claimed |
| WO-2005007601-A2 | SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | TPMT, NAT1, GOT1 | SIRT2 4238/4885NR1H4 331/4885ALDH1A1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.